A study exploring adjuvant capecitabine in early-stage TNBC failed but researchers are performing genomic analysis on a subset of patients who benefited.
Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.
The planned product, which will target drug-development companies, uses machine learning techniques to predict the outcomes and likelihood of success of clinical trials.
In this arm of the trial, 23 percent of patients treated with AKT1 E17K mutations saw their tumors shrink, a better result than those seen in three other trial arms.
The prospective, multi-site clinical trial will evaluate the clinical utility of unbiased sequencing for identifying pathogens in suspected CNS infections.
The clinical trial matching app, which Roche collaborated on with MolecularMatch, is the latest in a series of features that it will introduce in its tumor board solution.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
